Skip to main content
RGC logo

Regencell Bioscience Holdings Limited

RGCNASDAQHealthcareDrug Manufacturers - Specialty & Generic

$9.59Today:- (-)1Y −45.32%

As of Oct 16, 2026 close

Market cap
$4.71B
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$4.51$69.00
Volume (live)
-
Avg. volume (3M)
274.27K

Regencell Bioscience Holdings (RGC) Financial Ratios

For fiscal 2026 (fiscal year ended Jun 30, 2026), Regencell Bioscience Holdings had return on equity of -128.5% (down from -54.8%), debt-to-equity of 0.02 (down from 0.11), a current ratio of 10.77 (up from 7.39) and return on assets of -71.5% (down from -33.2%). A current ratio of 10.77 means current assets exceed current liabilities.

Regencell Bioscience Holdings Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021
Period endingJun 2026Jun 2025Jun 2024Jun 2023Jun 2022Jun 2021
Valuation Ratios
P/B Ratio226.041733.675.3225.0126.36-
Price/Tangible Book226.041733.675.3224.9226.39-
Enterprise Value Ratios
Profitability & Returns
Return on Equity (ROE)-128.52%-54.81%-43.18%-41.71%-116.10%-
Return on Assets (ROA)-71.54%-33.20%-28.11%-25.59%-51.87%-202.15%
Return on Capital Employed (ROCE)-87.40%-74.00%-57.50%-52.20%-43.70%34.60%
Leverage & Solvency Ratios
Debt/Equity0.020.110.010.040.04-0.92
Liquidity Ratios
Current Ratio10.777.3941.9219.1528.460.01
Quick Ratio10.757.3841.1319.0528.410.01
Efficiency Ratios
Yield & Distribution Ratios
Earnings Yield-0.39%-0.04%-9.84%-1.96%-1.65%-
FCF Yield-0.26%-0.04%-9.16%-1.66%-1.34%-
Buyback Yield-0.02%---1.62%-28.06%-

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Regencell Bioscience Holdings Financial Ratios

What is Regencell Bioscience Holdings's return on equity?

Regencell Bioscience Holdings's return on equity (ROE) was -128.5% for fiscal 2026 (period ended Jun 30, 2026). It was -54.8% a year earlier.

What is Regencell Bioscience Holdings's debt-to-equity ratio?

Regencell Bioscience Holdings's debt-to-equity ratio was 0.02 for fiscal 2026 (period ended Jun 30, 2026). It was 0.11 a year earlier.

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition